Progression-free survival (PFS) in oncology: caveat emptor!

被引：2
|
作者：
Sarac, Sinan B. [1 ]
Ainsworth, Mark A. [1 ,2 ]
Hovgaard, Doris [1 ]
Bjerrum, Ole W. [1 ]
机构：
[1] Danish Med Agcy, Med Evaluat & Biostat, Copenhagen, Denmark
[2] Odense Univ Hosp, Dept Med Gastroenterol, Odense, Denmark
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2019年 / 124卷 / 03期
关键词：
D O I：
10.1111/bcpt.13192
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：237 / 238
页数：2
相关论文
共 50 条
  • [1] Progression-free survival in oncology: Caveat emptor!
    Bergmann, Troels K.
    Christensen, Mette Marie H.
    Henriksen, Daniel P.
    Haastrup, Maija Bruun
    Damkier, Per
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 124 (03) : 240 - 244
  • [2] Response to Letter to the Editor concerning "Progression-free survival (PFS) in oncology: Caveat emptor!"
    Bergmann, Troels K.
    Christensen, Mette Marie H.
    Haastrup, Maija Bruun
    Damkier, Per
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 124 (03) : 239 - 239
  • [3] THE VALUE OF PROGRESSION-FREE SURVIVAL (PFS) AS AN ENDPOINT IN ONCOLOGY TRIALS
    Quinn, C.
    Palmer, S.
    Bruns, J.
    Grant, C.
    Sykes, D.
    Kaura, S.
    VALUE IN HEALTH, 2015, 18 (07) : A684 - A685
  • [4] Progression-free survival (PFS) as a surrogate for overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John
    Goss, Glenwood
    Fung-Kee-Fung, Michael
    Jonker, Derek
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population
    Clifton, K.
    Min, Yi
    Kimmel, J.
    Litton, J.
    Tripathy, D.
    Karuturi, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (03) : 667 - 674
  • [6] Progression-free survival (PFS) and toxicities of palbociclib in a geriatric population
    K. Clifton
    Yi Min
    J. Kimmel
    J. Litton
    D. Tripathy
    M. Karuturi
    Breast Cancer Research and Treatment, 2019, 175 : 667 - 674
  • [7] TERT as a prognostic factor for gliomas progression-free survival (PFS)
    Solis Hernandez, M. P.
    Faez, L.
    Cantero, D.
    Hernandez Lain, A.
    Sanchez Gomez, P.
    Ruano, Y.
    Galera, M. D. M.
    Sepulveda Sanchez, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John Frederick
    Goss, Glenwood D.
    Fung-Kee-Fung, Michael
    Jonker, Derek J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Rethinking Progression-Free Survival (PFS) as a Clinical Trials Surrogate for Overall Survival (OS)
    Stewart, D.
    Bosse, D.
    Ocana, A.
    Goss, G.
    Jonker, D.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1782 - S1782
  • [10] OVERALL SURVIVAL VERSUS PROGRESSION-FREE SURVIVAL IN ONCOLOGY CLINICAL TRIALS
    Aissaoui, A.
    Bin Sawad, A.
    Turkistani, F.
    Aissaoui, N.
    VALUE IN HEALTH, 2016, 19 (07) : A717 - A717
12345